{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:58:27Z","timestamp":1770814707526,"version":"3.50.1"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03151-z","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T08:26:39Z","timestamp":1766737599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineered nanoparticles for endocrine tumor targeting, current progress and future outlook"],"prefix":"10.1007","volume":"43","author":[{"given":"Maryam","family":"Aftab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zubair","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneeb","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amjad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"5","key":"3151_CR1","first-page":"38","volume":"117","author":"J Knight","year":"2021","unstructured":"Knight J. Endocrine system 1: overview of the endocrine system and hormones. Nurs Times. 2021;117(5):38\u201342.","journal-title":"Nurs Times"},{"issue":"3","key":"3151_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ecl.2018.05.003","volume":"47","author":"K \u00d6berg","year":"2018","unstructured":"\u00d6berg K. The genesis of the neuroendocrine tumors concept: from Oberndorfer to 2018. Endocrinol Metabolism Clin. 2018;47(3):711\u201331.","journal-title":"Endocrinol Metabolism Clin"},{"issue":"8","key":"3151_CR3","doi-asserted-by":"publisher","first-page":"T171","DOI":"10.1530\/ERC-18-0116","volume":"25","author":"TJ Giordano","year":"2018","unstructured":"Giordano TJ. 65 years of the double helix: classification of endocrine tumors in the age of integrated genomics. Endocrine-Relat Cancer. 2018;25(8):T171-87.","journal-title":"Endocrine-Relat Cancer"},{"issue":"1","key":"3151_CR4","doi-asserted-by":"publisher","first-page":"2390022","DOI":"10.1080\/10717544.2024.2390022","volume":"31","author":"L Liu","year":"2024","unstructured":"Liu L, Yang M, Chen Z. Surface functionalized nanomaterial systems for targeted therapy of endocrine related tumors: a review of recent advancements. Drug Deliv. 2024;31(1):2390022.","journal-title":"Drug Deliv"},{"issue":"3","key":"3151_CR5","first-page":"2715","volume":"15","author":"P Patel","year":"2018","unstructured":"Patel P, Galoian K. Molecular challenges of neuroendocrine tumors. Oncol Lett. 2018;15(3):2715\u201325.","journal-title":"Oncol Lett"},{"issue":"11","key":"3151_CR6","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376.","journal-title":"Mol Biol Rep"},{"key":"3151_CR7","doi-asserted-by":"publisher","first-page":"993081","DOI":"10.3389\/fendo.2022.993081","volume":"13","author":"Y Hou","year":"2023","unstructured":"Hou Y, et al. Applications of spatially resolved omics in the field of endocrine tumors. Front Endocrinol. 2023;13:993081.","journal-title":"Front Endocrinol"},{"key":"3151_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12022-018-9522-y","volume":"29","author":"S Uccella","year":"2018","unstructured":"Uccella S, et al. Immunohistochemical biomarkers of gastrointestinal, pancreatic, pulmonary, and thymic neuroendocrine neoplasms. Endocr Pathol. 2018;29:150\u201368.","journal-title":"Endocr Pathol"},{"issue":"18","key":"3151_CR9","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/cncr.28721","volume":"120","author":"H Sorbye","year":"2014","unstructured":"Sorbye H, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814\u201323.","journal-title":"Cancer"},{"key":"3151_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-017-1273-x","volume":"58","author":"E Leoncini","year":"2017","unstructured":"Leoncini E, et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017;58:368\u201379.","journal-title":"Endocrine"},{"issue":"22","key":"3151_CR11","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1093\/hmg\/ddaa268","volume":"29","author":"S Akhavanfard","year":"2020","unstructured":"Akhavanfard S, et al. Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma. Hum Mol Genet. 2020;29(22):3679\u201390.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"3151_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.path.2020.08.002","volume":"13","author":"JA Jarzembowski","year":"2020","unstructured":"Jarzembowski JA. New prognostic indicators in pediatric adrenal tumors: neuroblastoma and adrenal cortical tumors, can we predict when these will behave badly? Surg Pathol Clin. 2020;13(4):625\u201341.","journal-title":"Surg Pathol Clin"},{"issue":"3","key":"3151_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101428","volume":"34","author":"CD Kamilaris","year":"2020","unstructured":"Kamilaris CD, Hannah-Shmouni F, Stratakis CA. Adrenocortical tumorigenesis: lessons from genetics. Best Pract Res Clin Endocrinol Metab. 2020;34(3):101428.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"3151_CR14","first-page":"936031","volume":"2014","author":"TC Ribeiro","year":"2014","unstructured":"Ribeiro TC, et al. Amplification of the insulin-like growth factor 1 receptor gene is a rare event in adrenocortical adenocarcinomas: searching for potential mechanisms of overexpression. Biomed Res Int. 2014;2014(1):936031.","journal-title":"Biomed Res Int"},{"issue":"3","key":"3151_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/MED.0000000000000540","volume":"27","author":"VB Brondani","year":"2020","unstructured":"Brondani VB, Fragoso MCB. Pediatric adrenocortical tumor\u2013review and management update. Curr Opin Endocrinol Diabetes Obes. 2020;27(3):177\u201386.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"3151_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/08880018.2019.1710309","volume":"37","author":"W Zekri","year":"2020","unstructured":"Zekri W, et al. The outcome of childhood adrenocortical carcinoma in egypt: A model from developing countries. Pediatr Hematol Oncol. 2020;37(3):198\u2013210.","journal-title":"Pediatr Hematol Oncol"},{"key":"3151_CR17","doi-asserted-by":"crossref","unstructured":"Longui CA. Adrenal cortical carcinoma in infancy. 2019;37(1);02\u201303.","DOI":"10.1590\/1984-0462\/;2019;37;1;00021"},{"key":"3151_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12020-019-01869-1","volume":"64","author":"MC De Martino","year":"2019","unstructured":"De Martino MC, et al. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. Endocrine. 2019;64:673\u201384.","journal-title":"Endocrine"},{"key":"3151_CR19","doi-asserted-by":"publisher","first-page":"e935809","DOI":"10.12659\/MSM.935809","volume":"28","author":"S Andrei","year":"2022","unstructured":"Andrei S, et al. COVID-19 pandemic was associated with lower activity but not higher perioperative mortality in a large Eastern European center. Med Sci Monitor: Int Med J Experimental Clin Res. 2022;28:e935809\u20131.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"issue":"6","key":"3151_CR20","doi-asserted-by":"publisher","first-page":"R253","DOI":"10.1530\/ERC-11-0170","volume":"18","author":"J Welander","year":"2011","unstructured":"Welander J, S\u00f6derkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18(6):R253-76.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"3151_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1210\/jc.2009-1632","volume":"95","author":"N Van Duinen","year":"2010","unstructured":"Van Duinen N, et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metabolism. 2010;95(1):209\u201314.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"2","key":"3151_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2559.2010.03613.x","volume":"58","author":"AM McNicol","year":"2011","unstructured":"McNicol AM. Update on tumours of the adrenal cortex, phaeochromocytoma and extra-adrenal paraganglioma. Histopathology. 2011;58(2):155\u201368.","journal-title":"Histopathology"},{"issue":"11","key":"3151_CR23","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1210\/jcem.86.11.8034","volume":"86","author":"D Erickson","year":"2001","unstructured":"Erickson D, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metabolism. 2001;86(11):5210\u20136.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"3151_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00268-007-9360-4","volume":"32","author":"JA Lee","year":"2008","unstructured":"Lee JA, Duh Q-Y. Sporadic paraganglioma. World J Surg. 2008;32:683\u20137.","journal-title":"World J Surg"},{"issue":"11","key":"3151_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59111925","volume":"59","author":"M-D T\u0103n\u0103sescu","year":"2023","unstructured":"T\u0103n\u0103sescu M-D, et al. Paragangliomas and anemia: literature review and case report. Medicina (Kaunas). 2023;59(11):1925.","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"3151_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metabolism. 2014;99(6):1915\u201342.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"3151_CR27","doi-asserted-by":"publisher","unstructured":"Kantorovich V, Pacak K. New insights on the pathogenesis of paraganglioma and pheochromocytoma. F1000Research. 2018;7:F1000-Faculty. https:\/\/doi.org\/10.12688\/f1000research.14568.1","DOI":"10.12688\/f1000research.14568.1"},{"issue":"2","key":"3151_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101346","volume":"34","author":"E Sbardella","year":"2020","unstructured":"Sbardella E, Grossman AB. Pheochromocytoma: an approach to diagnosis. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101346.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"3151_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/ssj.ssj_77_21","volume":"9","author":"W Osman","year":"2021","unstructured":"Osman W, et al. Adrenalectomies: clinical findings, laboratory, and histological findings. Saudi Surg J. 2021;9(1):12\u20138.","journal-title":"Saudi Surg J"},{"key":"3151_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000345675","volume":"41","author":"GN Hendy","year":"2013","unstructured":"Hendy GN, Cole DE. Genetic defects associated with familial and sporadic hyperparathyroidism. Front Horm Res. 2013;41:149\u201365.","journal-title":"Front Horm Res"},{"issue":"7","key":"3151_CR31","doi-asserted-by":"publisher","first-page":"R441","DOI":"10.1530\/ERC-19-0135","volume":"26","author":"F Cetani","year":"2019","unstructured":"Cetani F, et al. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocrine-related Cancer. 2019;26(7):R441\u201364.","journal-title":"Endocrine-related Cancer"},{"key":"3151_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-021-02123-7","volume":"19","author":"A Galani","year":"2021","unstructured":"Galani A, et al. Atypical parathyroid adenoma: clinical and anatomical pathologic features. World J Surg Oncol. 2021;19:1\u20139.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"3151_CR33","first-page":"275802","volume":"2011","author":"MI Alvelos","year":"2011","unstructured":"Alvelos MI, Mendes M, Soares P. Molecular alterations in sporadic primary hyperparathyroidism. Genet Res Int. 2011;2011(1):275802.","journal-title":"Genet Res Int"},{"key":"3151_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11060-013-1354-5","volume":"117","author":"ED Aflorei","year":"2014","unstructured":"Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol. 2014;117:379\u201394.","journal-title":"J Neurooncol"},{"issue":"3","key":"3151_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cncr.20412","volume":"101","author":"S Ezzat","year":"2004","unstructured":"Ezzat S, et al. The prevalence of pituitary adenomas: a systematic review. Cancer: Interdisciplinary Int J Am Cancer Soc. 2004;101(3):613\u20139.","journal-title":"Cancer: Interdisciplinary Int J Am Cancer Soc"},{"issue":"3","key":"3151_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","volume":"41","author":"T Mindermann","year":"1994","unstructured":"Mindermann T, Wilson CB. Age-related and gender\u2010related occurrence of pituitary adenomas. Clin Endocrinol. 1994;41(3):359\u201364.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"3151_CR37","first-page":"168","volume":"85","author":"MR Drange","year":"2000","unstructured":"Drange MR, et al. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metabolism. 2000;85(1):168\u201374.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"3151_CR38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.wneu.2019.03.049","volume":"127","author":"D Solari","year":"2019","unstructured":"Solari D, et al. Pituitary adenomas: what are the key features? What are the current treatments? Where is the future taking us? World Neurosurg. 2019;127:695\u2013709.","journal-title":"World Neurosurg"},{"issue":"10","key":"3151_CR39","doi-asserted-by":"publisher","first-page":"T195","DOI":"10.1530\/ERC-17-0243","volume":"24","author":"R Alrezk","year":"2017","unstructured":"Alrezk R, Hannah-Shmouni F, Stratakis CA. MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer. 2017;24(10):T195-208.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"3151_CR40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3892\/ol.2011.236","volume":"2","author":"AJ Al-Qasem","year":"2011","unstructured":"Al-Qasem AJ, et al. TP53 genetic alterations in Arab breast cancer patients: novel mutations, pattern and distribution. Oncol Lett. 2011;2(2):363\u20139.","journal-title":"Oncol Lett"},{"key":"3151_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.gene.2018.10.044","volume":"684","author":"N Younes","year":"2019","unstructured":"Younes N, Zayed H. Genetic epidemiology of ovarian cancer in the 22 Arab countries: a systematic review. Gene. 2019;684:154\u201364.","journal-title":"Gene"},{"key":"3151_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10549-017-4635-4","volume":"168","author":"A-J Alhuqail","year":"2018","unstructured":"Alhuqail A-J, et al. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in Arab breast and ovarian cancer patients. Breast Cancer Res Treat. 2018;168:695\u2013702.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"3151_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1634\/theoncologist.2014-0364","volume":"20","author":"NS El Saghir","year":"2015","unstructured":"El Saghir NS, et al. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. Oncologist. 2015;20(4):357\u201364.","journal-title":"Oncologist"},{"issue":"1","key":"3151_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41525-019-0110-y","volume":"5","author":"FS AlHarthi","year":"2020","unstructured":"AlHarthi FS, et al. Familial\/inherited cancer syndrome: a focus on the highly consanguineous Arab population. NPJ Genomic Med. 2020;5(1):3.","journal-title":"NPJ Genomic Med"},{"issue":"16","key":"3151_CR45","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2174\/0113892010275850240102105033","volume":"25","author":"RN Prajapati","year":"2024","unstructured":"Prajapati RN, et al. Recent advances in pharmaceutical design: unleashing the potential of novel therapeutics. Curr Pharm Biotechnol. 2024;25(16):2060\u201377.","journal-title":"Curr Pharm Biotechnol"},{"key":"3151_CR46","doi-asserted-by":"crossref","unstructured":"Sun T et al. Engineered nanoparticles for drug delivery in cancer therapy. Nanomaterials and neoplasms, 2021: pp. 31\u2013142.","DOI":"10.1201\/9780429027819-2"},{"key":"3151_CR47","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S87148","author":"B Fonseca-Santos","year":"2015","unstructured":"Fonseca-Santos B, Gremi\u00e3o MPD, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease. Int J Nanomedicine. 2015;4981\u20135003. https:\/\/doi.org\/10.2147\/IJN.S87148.","journal-title":"Int J Nanomedicine"},{"key":"3151_CR48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3151_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/pharmaceutics10030151","volume":"10","author":"M Sarfraz","year":"2018","unstructured":"Sarfraz M, et al. Development of dual drug loaded nanosized liposomal formulation by a reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies. Pharmaceutics. 2018;10(3):151.","journal-title":"Pharmaceutics"},{"key":"3151_CR50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s13346-018-0587-4","volume":"9","author":"M Sedighi","year":"2019","unstructured":"Sedighi M, et al. Rapid optimization of liposome characteristics using a combined microfluidics and design-of-experiment approach. Drug Delivery Translational Res. 2019;9:404\u201313.","journal-title":"Drug Delivery Translational Res"},{"key":"3151_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.actbio.2019.10.003","volume":"101","author":"SB Brown","year":"2020","unstructured":"Brown SB, et al. Effects of cartilage-targeting moieties on nanoparticle biodistribution in healthy and Osteoarthritic joints. Acta Biomater. 2020;101:469\u201383.","journal-title":"Acta Biomater"},{"key":"3151_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-019-0451-9","volume":"17","author":"C-x Zhang","year":"2019","unstructured":"Zhang C-x, et al. Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. J Nanobiotechnol. 2019;17:1\u201316.","journal-title":"J Nanobiotechnol"},{"issue":"49","key":"3151_CR53","doi-asserted-by":"publisher","first-page":"42186","DOI":"10.1021\/acsami.8b18979","volume":"10","author":"Z Le","year":"2018","unstructured":"Le Z, et al. Hydrogen-bonded tannic acid-based anticancer nanoparticle for enhancement of oral chemotherapy. ACS Appl Mater Interfaces. 2018;10(49):42186\u201397.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3151_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.actbio.2019.12.005","volume":"103","author":"C He","year":"2020","unstructured":"He C, et al. SiRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery. Acta Biomater. 2020;103:213\u201322.","journal-title":"Acta Biomater"},{"key":"3151_CR55","doi-asserted-by":"publisher","first-page":"110768","DOI":"10.1016\/j.msec.2020.110768","volume":"111","author":"L Zhang","year":"2020","unstructured":"Zhang L, et al. Microfluidic-assisted polymer-protein assembly to fabricate homogeneous functionalnanoparticles. Mater Sci Engineering: C. 2020;111:110768.","journal-title":"Mater Sci Engineering: C"},{"issue":"23","key":"3151_CR56","doi-asserted-by":"publisher","first-page":"8572","DOI":"10.1039\/C8CS00162F","volume":"47","author":"E Rideau","year":"2018","unstructured":"Rideau E, et al. Liposomes and polymersomes: a comparative review towards cell mimicking. Chem Soc Rev. 2018;47(23):8572\u2013610.","journal-title":"Chem Soc Rev"},{"issue":"3","key":"3151_CR57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","volume":"14","author":"D Shae","year":"2019","unstructured":"Shae D, et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019;14(3):269\u201378.","journal-title":"Nat Nanotechnol"},{"issue":"6","key":"3151_CR58","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1073\/pnas.1916395117","volume":"117","author":"C Zelmer","year":"2020","unstructured":"Zelmer C, et al. Organelle-specific targeting of polymersomes into the cell nucleus. Proc Natl Acad Sci. 2020;117(6):2770\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"3151_CR59","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1021\/acsabm.9b01185","volume":"3","author":"X Liu","year":"2020","unstructured":"Liu X, et al. Glucose and H2O2 dual-responsive polymeric micelles for the self-regulated release of insulin. ACS Appl Bio Mater. 2020;3(3):1598\u2013606.","journal-title":"ACS Appl Bio Mater"},{"issue":"1","key":"3151_CR60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4143\/crt.2016.376","volume":"50","author":"S-W Lee","year":"2018","unstructured":"Lee S-W, et al. An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of Paclitaxel as first-line treatment for ovarian cancer: a Korean gynecologic oncology group study (KGOG-3021). Cancer Res Treatment: Official J Korean Cancer Association. 2018;50(1):195\u2013203.","journal-title":"Cancer Res Treatment: Official J Korean Cancer Association"},{"issue":"1","key":"3151_CR61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/cn400182z","volume":"5","author":"L Xu","year":"2014","unstructured":"Xu L, Zhang H, Wu Y. Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci. 2014;5(1):2\u201313.","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"3151_CR62","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3390\/molecules22091401","volume":"22","author":"L Palmerston Mendes","year":"2017","unstructured":"Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22(9):1401.","journal-title":"Molecules"},{"key":"3151_CR63","doi-asserted-by":"publisher","first-page":"e00109","DOI":"10.1016\/j.susmat.2019.e00109","volume":"22","author":"W Yang","year":"2019","unstructured":"Yang W, et al. Gold nanoparticle based photothermal therapy: development and application for effective cancer treatment. Sustainable Mater Technol. 2019;22:e00109.","journal-title":"Sustainable Mater Technol"},{"key":"3151_CR64","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo D, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373\u201387.","journal-title":"Pharm Res"},{"issue":"2","key":"3151_CR65","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/antibiotics7020046","volume":"7","author":"LS Arias","year":"2018","unstructured":"Arias LS, et al. Iron oxide nanoparticles for biomedical applications: a perspective on synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics. 2018;7(2):46.","journal-title":"Antibiotics"},{"issue":"3","key":"3151_CR66","doi-asserted-by":"publisher","first-page":"eaax5032","DOI":"10.1126\/sciadv.aax5032","volume":"6","author":"K-W Huang","year":"2020","unstructured":"Huang K-W, et al. Highly efficient and tumor-selective nanoparticles for dual-targeted Immunogene therapy against cancer. Sci Adv. 2020;6(3):eaax5032.","journal-title":"Sci Adv"},{"issue":"10","key":"3151_CR67","doi-asserted-by":"publisher","first-page":"12148","DOI":"10.1021\/acsnano.9b06691","volume":"13","author":"C Xu","year":"2019","unstructured":"Xu C, et al. Positron emission tomography-guided photodynamic therapy with biodegradable mesoporous silica nanoparticles for personalized cancer immunotherapy. ACS Nano. 2019;13(10):12148\u201361.","journal-title":"ACS Nano"},{"key":"3151_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.02.039","volume":"127","author":"BB Manshian","year":"2017","unstructured":"Manshian BB, et al. Personalized medicine and follow-up of therapeutic delivery through exploitation of quantum dot toxicity. Biomaterials. 2017;127:1\u201312.","journal-title":"Biomaterials"},{"issue":"2","key":"3151_CR69","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1021\/acs.bioconjchem.4c00576","volume":"36","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Ferritin versus liposomes: A comparative analysis of Protein-and Lipid-Based drug delivery systems. Bioconjug Chem. 2025;36(2):127\u201335.","journal-title":"Bioconjug Chem"},{"issue":"09","key":"3151_CR70","first-page":"01","volume":"13","author":"C Jaiswal","year":"2022","unstructured":"Jaiswal C, et al. Nanoparticle aided tumor targeting and cancer detection. J Adv Sci Res. 2022;13(09):01\u201311.","journal-title":"J Adv Sci Res"},{"issue":"12","key":"3151_CR71","doi-asserted-by":"publisher","first-page":"2008171","DOI":"10.1002\/adfm.202008171","volume":"31","author":"Q Liu","year":"2021","unstructured":"Liu Q, et al. Inorganic nanoparticles applied as functional therapeutics. Adv Funct Mater. 2021;31(12):2008171.","journal-title":"Adv Funct Mater"},{"issue":"1","key":"3151_CR72","volume":"2018","author":"BP Joshi","year":"2018","unstructured":"Joshi BP, Wang TD. Targeted optical imaging agents in cancer: focus on clinical applications. Contrast Media Mol Imaging. 2018;2018(1):2015237.","journal-title":"Contrast Media Mol Imaging"},{"issue":"9","key":"3151_CR73","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1039\/c3nr00421j","volume":"5","author":"NA Harun","year":"2013","unstructured":"Harun NA, et al. Gold nanoparticle-enhanced luminescence of silicon quantum dots co-encapsulated in polymer nanoparticles. Nanoscale. 2013;5(9):3817\u201327.","journal-title":"Nanoscale"},{"issue":"5","key":"3151_CR74","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3390\/s17051078","volume":"17","author":"H Zhang","year":"2017","unstructured":"Zhang H, Lv J, Jia Z. Efficient fluorescence resonance energy transfer between quantum dots and gold nanoparticles based on porous silicon photonic crystal for DNA detection. Sensors. 2017;17(5):1078.","journal-title":"Sensors"},{"issue":"10","key":"3151_CR75","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1039\/c0nr00359j","volume":"2","author":"X Wu","year":"2010","unstructured":"Wu X, et al. Ultrasmall near-infrared gold nanoclusters for tumor fluorescence imaging in vivo. Nanoscale. 2010;2(10):2244\u20139.","journal-title":"Nanoscale"},{"issue":"11","key":"3151_CR76","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.addr.2010.07.004","volume":"62","author":"JR McCarthy","year":"2010","unstructured":"McCarthy JR. Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Adv Drug Deliv Rev. 2010;62(11):1023\u201330.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"3151_CR77","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.addr.2010.07.009","volume":"62","author":"J Xie","year":"2010","unstructured":"Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064\u201379.","journal-title":"Adv Drug Deliv Rev"},{"issue":"21","key":"3151_CR78","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1039\/D4TB00478G","volume":"12","author":"T Liu","year":"2024","unstructured":"Liu T, et al. Lysosomal-targeted fluorescent probe based pH regulating reactivity for tracking cysteine dynamics under oxidative stress. J Mater Chem B. 2024;12(21):5157\u201361.","journal-title":"J Mater Chem B"},{"issue":"11","key":"3151_CR79","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1016\/j.chempr.2023.06.011","volume":"9","author":"C Lu","year":"2023","unstructured":"Lu C, et al. Tumor microenvironment-tailored nanoplatform for companion diagnostic applications of precise cancer therapy. Chem. 2023;9(11):3185\u2013211.","journal-title":"Chem"},{"issue":"1","key":"3151_CR80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40005-017-0370-4","volume":"48","author":"YH Choi","year":"2018","unstructured":"Choi YH, Han H-K. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Invest. 2018;48(1):43\u201360.","journal-title":"J Pharm Invest"},{"issue":"2","key":"3151_CR81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discovery"},{"issue":"7291","key":"3151_CR82","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis ME, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067\u201370.","journal-title":"Nature"},{"issue":"47","key":"3151_CR83","doi-asserted-by":"publisher","first-page":"77348","DOI":"10.18632\/oncotarget.12668","volume":"7","author":"SY Song","year":"2016","unstructured":"Song SY, et al. Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer model. Oncotarget. 2016;7(47):77348.","journal-title":"Oncotarget"},{"key":"3151_CR84","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jconrel.2019.01.009","volume":"295","author":"F Mottaghitalab","year":"2019","unstructured":"Mottaghitalab F, et al. New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment. J Controlled Release. 2019;295:250\u201367.","journal-title":"J Controlled Release"},{"issue":"9","key":"3151_CR85","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.biomaterials.2012.12.017","volume":"34","author":"W She","year":"2013","unstructured":"She W, et al. Dendronized heparin\u2009\u2013\u2009doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials. 2013;34(9):2252\u201364.","journal-title":"Biomaterials"},{"issue":"11","key":"3151_CR86","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.biomaterials.2012.12.040","volume":"34","author":"L Pan","year":"2013","unstructured":"Pan L, et al. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials. 2013;34(11):2719\u201330.","journal-title":"Biomaterials"},{"key":"3151_CR87","doi-asserted-by":"crossref","unstructured":"Huynh E, Zheng G. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Taylor & Francis; 2015. pp. 1993\u20135.","DOI":"10.2217\/nnm.15.86"},{"key":"3151_CR88","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fbioe.2019.00415","volume":"7","author":"OS Thomas","year":"2019","unstructured":"Thomas OS, Weber W. Overcoming physiological barriers to nanoparticle delivery\u2014are we there yet? Front Bioeng Biotechnol. 2019;7:415.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"3151_CR89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40580-019-0193-2","volume":"6","author":"P Navya","year":"2019","unstructured":"Navya P, et al. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Convergence. 2019;6(1):23.","journal-title":"Nano Convergence"},{"issue":"10","key":"3151_CR90","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","volume":"8","author":"MM Schmidt","year":"2009","unstructured":"Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861\u201371.","journal-title":"Mol Cancer Ther"},{"key":"3151_CR91","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jconrel.2014.06.038","volume":"190","author":"B Yameen","year":"2014","unstructured":"Yameen B, et al. Insight into nanoparticle cellular uptake and intracellular targeting. J Controlled Release. 2014;190:485\u201399.","journal-title":"J Controlled Release"},{"issue":"2","key":"3151_CR92","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","volume":"148","author":"F Danhier","year":"2010","unstructured":"Danhier F, Feron O, Pr\u00e9at V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Controlled Release. 2010;148(2):135\u201346.","journal-title":"J Controlled Release"},{"key":"3151_CR93","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E P\u00e9rez-Herrero","year":"2015","unstructured":"P\u00e9rez-Herrero E, Fern\u00e1ndez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52\u201379.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"3151_CR94","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771\u201382.","journal-title":"Nat Rev Drug Discov"},{"key":"3151_CR95","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.pdpdt.2022.102915","volume":"39","author":"VR Shinde","year":"2022","unstructured":"Shinde VR, et al. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagn Photodyn Ther. 2022;39:102915.","journal-title":"Photodiagn Photodyn Ther"},{"issue":"13","key":"3151_CR96","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3390\/polym14132601","volume":"14","author":"V Ejigah","year":"2022","unstructured":"Ejigah V, et al. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers. 2022;14(13):2601.","journal-title":"Polymers"},{"issue":"1","key":"3151_CR97","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","volume":"41","author":"H Maeda","year":"2001","unstructured":"Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41(1):189\u2013207.","journal-title":"Adv Enzyme Regul"},{"issue":"3","key":"3151_CR98","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3151_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/138955711793564024","volume":"11","author":"L Arias","year":"2011","unstructured":"Arias L. Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem. 2011;11(1):1\u201317.","journal-title":"Mini Rev Med Chem"},{"issue":"5","key":"3151_CR100","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1021\/bc100070g","volume":"21","author":"H Maeda","year":"2010","unstructured":"Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21(5):797\u2013802.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"3151_CR101","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.addr.2010.09.003","volume":"63","author":"K Maruyama","year":"2011","unstructured":"Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63(3):161\u20139.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"3151_CR102","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1021\/acs.chemrev.0c00779","volume":"121","author":"M Izci","year":"2021","unstructured":"Izci M, et al. The use of alternative strategies for enhanced nanoparticle delivery to solid tumors. Chem Rev. 2021;121(3):1746\u2013803.","journal-title":"Chem Rev"},{"issue":"1","key":"3151_CR103","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.chembiol.2006.11.015","volume":"14","author":"S Hong","year":"2007","unstructured":"Hong S, et al. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol. 2007;14(1):107\u201315.","journal-title":"Chem Biol"},{"key":"3151_CR104","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2021.07.038","volume":"337","author":"A Banstola","year":"2021","unstructured":"Banstola A, et al. Recent progress in stimuli-responsive nanosystems for inducing Immunogenic cell death. J Controlled Release. 2021;337:505\u201320.","journal-title":"J Controlled Release"},{"key":"3151_CR105","doi-asserted-by":"publisher","first-page":"153303382312059","DOI":"10.1177\/15330338231205999","volume":"22","author":"A Jafari","year":"2023","unstructured":"Jafari A, et al. The emerging role of exosomal miRNAs as biomarkers for early cancer detection: a comprehensive literature review. Technol Cancer Res Treat. 2023;22:15330338231206000.","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"3151_CR106","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12032-022-01887-6","volume":"40","author":"L Rezakhani","year":"2022","unstructured":"Rezakhani L, et al. Exosomes: special nano-therapeutic carrier for cancers, overview on anticancer drugs. Med Oncol. 2022;40(1):31.","journal-title":"Med Oncol"},{"issue":"1","key":"3151_CR107","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12935-021-02059-8","volume":"21","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, et al. The significance of exosomal RNAs in the development, diagnosis, and treatment of pancreatic cancer. Cancer Cell Int. 2021;21(1):364.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"3151_CR108","first-page":"1331","volume":"17","author":"ES Bernad","year":"2025","unstructured":"Bernad ES, et al. Extracellular vesicles and nanoparticles in regenerative and personalised medicine: diagnostic and therapeutic Roles\u2014A. Narrative Rev Pharm. 2025;17(10):1331.","journal-title":"Narrative Rev Pharm"},{"key":"3151_CR109","unstructured":"S\u00f6zmen AB. Development of Optical Sensor Platforms for Exosome Detection. 2024."},{"issue":"2","key":"3151_CR110","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1021\/acsbiomaterials.2c01329","volume":"9","author":"R Kar","year":"2023","unstructured":"Kar R, et al. Exosome-based smart drug delivery tool for cancer theranostics. ACS Biomaterials Sci Eng. 2023;9(2):577\u201394.","journal-title":"ACS Biomaterials Sci Eng"},{"key":"3151_CR111","doi-asserted-by":"publisher","unstructured":"Fr\u00f6hlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomed. 2012;7:5577\u201391. https:\/\/doi.org\/10.2147\/IJN.S36111","DOI":"10.2147\/IJN.S36111"},{"issue":"1","key":"3151_CR112","first-page":"5194780","volume":"2020","author":"R Zein","year":"2020","unstructured":"Zein R, Sharrouf W, Selting K. Physical properties of nanoparticles that result in improved cancer targeting. J Oncol. 2020;2020(1):5194780.","journal-title":"J Oncol"},{"key":"3151_CR113","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","volume":"130","author":"SK Golombek","year":"2018","unstructured":"Golombek SK, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17\u201338.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"3151_CR114","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.7150\/thno.21670","volume":"8","author":"H Lee","year":"2018","unstructured":"Lee H, et al. Companion diagnostic 64Cu-liposome positron emission tomography enables characterization of drug delivery to tumors and predicts response to cancer nanomedicines. Theranostics. 2018;8(9):2300.","journal-title":"Theranostics"},{"issue":"5","key":"3151_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, et al. Analysis of nanoparticle delivery to tumours. Nat Reviews Mater. 2016;1(5):1\u201312.","journal-title":"Nat Reviews Mater"},{"issue":"4","key":"3151_CR116","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1021\/mp800030k","volume":"5","author":"LE van Vlerken","year":"2008","unstructured":"van Vlerken LE, et al. Biodistribution and Pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm. 2008;5(4):516\u201326.","journal-title":"Mol Pharm"},{"issue":"1","key":"3151_CR117","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, et al. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410.","journal-title":"Nat Commun"},{"issue":"8","key":"3151_CR118","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1021\/acsbiomaterials.2c00594","volume":"8","author":"D Chaudhari","year":"2022","unstructured":"Chaudhari D, et al. Unfolding the potency of adenosine in targeting triple negative breast cancer via paclitaxel-incorporated pH-responsive stealth liposomes. ACS Biomaterials Sci Eng. 2022;8(8):3473\u201384.","journal-title":"ACS Biomaterials Sci Eng"},{"key":"3151_CR119","doi-asserted-by":"publisher","first-page":"124890","DOI":"10.1016\/j.ijpharm.2024.124890","volume":"667","author":"T Date","year":"2024","unstructured":"Date T, et al. Launching triple-hit chemo attack on TNBC through nanoparticle-mediated codelivery of cisplatin-chlorambucil conjugate and venetoclax. Int J Pharm. 2024;667:124890.","journal-title":"Int J Pharm"},{"issue":"7","key":"3151_CR120","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nbt.2614","volume":"31","author":"G Sahay","year":"2013","unstructured":"Sahay G, et al. Efficiency of SiRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013;31(7):653\u20138.","journal-title":"Nat Biotechnol"},{"key":"3151_CR121","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.etap.2016.07.003","volume":"46","author":"E Fr\u00f6hlich","year":"2016","unstructured":"Fr\u00f6hlich E. Cellular elimination of nanoparticles. Environ Toxicol Pharmacol. 2016;46:90\u20134.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"4","key":"3151_CR122","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jpm7040012","volume":"7","author":"C Fornaguera","year":"2017","unstructured":"Fornaguera C, Garc\u00eda-Celma MJ. Personalized nanomedicine: a revolution at the nanoscale. J Personalized Med. 2017;7(4):12.","journal-title":"J Personalized Med"},{"issue":"7","key":"3151_CR123","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/cea.12760","volume":"46","author":"E Wenande","year":"2016","unstructured":"Wenande E, Garvey L. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46(7):907\u201322.","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"3151_CR124","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3390\/app15063189","volume":"15","author":"I-A Vagena","year":"2025","unstructured":"Vagena I-A, et al. Enhancement of EPR effect for passive tumor targeting: current status and future perspectives. Appl Sci. 2025;15(6):3189.","journal-title":"Appl Sci"},{"key":"3151_CR125","doi-asserted-by":"publisher","first-page":"1002303","DOI":"10.37349\/etat.2025.1002303","volume":"6","author":"BA Cesca","year":"2025","unstructured":"Cesca BA, et al. State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches. Explor Target Anti-tumor Therapy. 2025;6:1002303.","journal-title":"Explor Target Anti-tumor Therapy"},{"issue":"2","key":"3151_CR126","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/17425247.2021.1874916","volume":"19","author":"R Islam","year":"2022","unstructured":"Islam R, Maeda H, Fang J. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and Pathoanatomic features, drug formulations and physicochemical factors. Expert Opin Drug Deliv. 2022;19(2):199\u2013212.","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"3151_CR127","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/jpm11060571","volume":"11","author":"MA Subhan","year":"2021","unstructured":"Subhan MA, et al. Recent advances in tumor targeting via EPR effect for cancer treatment. J Personalized Med. 2021;11(6):571.","journal-title":"J Personalized Med"},{"key":"3151_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152346","author":"E Rama","year":"2025","unstructured":"Rama E, et al. Image-guided strategies to improve drug delivery to tumors beyond using the enhanced permeability and retention (EPR) effect. Biochem Biophys Res Commun. 2025. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152346.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"3151_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14091919","volume":"14","author":"T Yang","year":"2022","unstructured":"Yang T, et al. \u201cTargeting design\u201d of nanoparticles in tumor therapy. Pharmaceutics. 2022;14(9):1919.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3151_CR130","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1021\/acs.chemrev.1c00484","volume":"122","author":"L Taiariol","year":"2021","unstructured":"Taiariol L, et al. Click and bioorthogonal chemistry: the future of active targeting of nanoparticles for nanomedicines? Chem Rev. 2021;122(1):340\u201384.","journal-title":"Chem Rev"},{"issue":"1","key":"3151_CR131","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41232-024-00329-2","volume":"44","author":"N Hosen","year":"2024","unstructured":"Hosen N. Identification of cancer-specific cell surface targets for CAR-T cell therapy. Inflamm Regeneration. 2024;44(1):17.","journal-title":"Inflamm Regeneration"},{"issue":"1","key":"3151_CR132","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/10717544.2022.2039804","volume":"29","author":"J-J Xu","year":"2022","unstructured":"Xu J-J, et al. Metal nanoparticles as a promising technology in targeted cancer treatment. Drug Deliv. 2022;29(1):664\u201378.","journal-title":"Drug Deliv"},{"key":"3151_CR133","doi-asserted-by":"crossref","unstructured":"Patel DM, Patel NN, Patel JK. Nanomedicine scale-up technologies: feasibilities and challenges, in Emerging technologies for nanoparticle manufacturing. Springer; 2021. pp. 511\u201339.","DOI":"10.1007\/978-3-030-50703-9_24"},{"key":"3151_CR134","doi-asserted-by":"publisher","unstructured":"Bidlingmaier M et al. Applying precision medicine to the diagnosis and management of endocrine disorders. Endocr Connections 2022;11(10). https:\/\/doi.org\/10.1530\/EC-22-0177","DOI":"10.1530\/EC-22-0177"},{"issue":"11","key":"3151_CR135","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3390\/nano11112991","volume":"11","author":"LM Ernst","year":"2021","unstructured":"Ernst LM, et al. The interactions between nanoparticles and the innate immune system from a nanotechnologist perspective. Nanomaterials. 2021;11(11):2991.","journal-title":"Nanomaterials"},{"key":"3151_CR136","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","volume":"351","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim M, et al. Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of pegylated products. J Controlled Release. 2022;351:215\u201330.","journal-title":"J Controlled Release"},{"issue":"36","key":"3151_CR137","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.2174\/0929867328666210406115529","volume":"28","author":"I Cs\u00f3ka","year":"2021","unstructured":"Cs\u00f3ka I, et al. Regulatory considerations, challenges and risk-based approach in nanomedicine development. Curr Med Chem. 2021;28(36):7461\u201376.","journal-title":"Curr Med Chem"},{"key":"3151_CR138","doi-asserted-by":"publisher","first-page":"1170264","DOI":"10.3389\/fonc.2023.1170264","volume":"13","author":"V Salemme","year":"2023","unstructured":"Salemme V, et al. The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. Front Oncol. 2023;13:1170264.","journal-title":"Front Oncol"},{"key":"3151_CR139","doi-asserted-by":"publisher","first-page":"173832","DOI":"10.1016\/j.ejphar.2020.173832","volume":"893","author":"D Ezhilarasan","year":"2021","unstructured":"Ezhilarasan D. Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist\u2019s perspectives. Eur J Pharmacol. 2021;893:173832.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3151_CR140","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","volume":"16","author":"S Gavas","year":"2021","unstructured":"Gavas S, Quazi S, Karpi\u0144ski TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021;16(1):173.","journal-title":"Nanoscale Res Lett"},{"issue":"9","key":"3151_CR141","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41578-021-00315-x","volume":"6","author":"J Wang","year":"2021","unstructured":"Wang J, Li Y, Nie G. Multifunctional biomolecule nanostructures for cancer therapy. Nat Rev Mater. 2021;6(9):766\u201383.","journal-title":"Nat Rev Mater"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03151-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:03:12Z","timestamp":1770393792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03151-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":141,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3151"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03151-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no competing interests that can influence the work reported in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"68"}}